Kosei Hasegawa

Revisiting Adrenal Crisis Triggered by Influenza Infection: Lessons from Two Fatal Cases.

Journal: Acta medica Okayama

Published: April 23, 2026

Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework.

Journal: Journal of gynecologic oncology

Published: April 15, 2026

MRI Findings of Uterine Adenofibroma With Squamous Metaplasia.

Journal: Cureus

Published: March 18, 2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Journal: The Lancet. Oncology

Published: February 24, 2026

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Journal: Lancet (London, England)

Published: February 04, 2026

Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).

Journal: Gynecologic oncology

Published: January 18, 2026

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 17, 2025

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Journal: Cancer science

Published: December 10, 2025

Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST)　- A Prospective Multicenter Study.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: December 03, 2025

cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

Journal: Journal of gynecologic oncology

Published: October 10, 2025

Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome.

Journal: The Journal of clinical endocrinology and metabolism

Published: October 02, 2025

Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 19, 2025

Revisiting Adrenal Crisis Triggered by Influenza Infection: Lessons from Two Fatal Cases.

Revisiting Adrenal Crisis Triggered by Influenza Infection: Lessons from Two Fatal Cases.

Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework.

Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework.

MRI Findings of Uterine Adenofibroma With Squamous Metaplasia.

MRI Findings of Uterine Adenofibroma With Squamous Metaplasia.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).

Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST) - A Prospective Multicenter Study.

Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST) - A Prospective Multicenter Study.

cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome.

Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome.

Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.

Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.

Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST)　- A Prospective Multicenter Study.

Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST)　- A Prospective Multicenter Study.